What does this research mean for the field?

MRI-guided laser interstitial thermal therapy (LITT) is a safe and feasible minimally invasive treatment for pediatric patients with drug-resistant epilepsy and brain tumors, and allows for safe same-session stereotactic biopsy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the indications, safety profile, and early clinical outcomes of MRI-guided laser interstitial thermal therapy (LITT) in children, including the feasibility of concurrent stereotactic biopsy.

September 4, 2026Child s Nervous SystemOpen Access

Laser interstitial thermal therapy in pediatric neurosurgery: a prospective nationwide study on indications, safety, and early outcomes

View Full Paper

Ask AI

Bookmark

Authors

SNSilas Haahr Nielsen JFJon Foss-Skiftesvik TMTorstein Melling

Discussion

Member takes

Overview

Prospective cohort study demonstrates favorable safety and seizure control from laser interstitial thermal therapy in pediatric patients, suggesting it is a viable minimally invasive option.

Key Points

To evaluate the indications, safety profile, and early clinical outcomes of MRI-guided laser interstitial thermal therapy (LITT) in children, including the feasibility of concurrent stereotactic biopsy.
Prospective cohort study of consecutive pediatric patients (age ≤ 18 years, N=27) treated with LITT at the Danish national referral center from June 2021 to October 2025.
Indications included drug-resistant epilepsy (n=18) and intracranial tumors (n=9), with 10 patients undergoing same-session stereotactic biopsy.
Outcomes measured included intraoperative adverse events, new neurological deficits, hospital stay, 30-day readmissions, Engel class seizure status, and tumor response on follow-up MRI.
Zero intraoperative complications or 30-day readmissions occurred; transient neurological deficits developed in 8 patients and persistent deficits in 3, with hospital stay ≤ 2 days for 23 of 27 patients.
In epilepsy cases, seizure freedom (Engel class I) was achieved in 71% of patients at 6 months, 63% at 12 months, and 57% at 24 months.
Tumor control was documented on follow-up MRI in 4 of 5 cases over a median follow-up of 15 months, and same-session stereotactic biopsy was successfully performed in 10 patients without biopsy-related complications.

Cite This Study

Nielsen et al. (2026) studied this question.

synapsesocial.com/papers/6a9a85345d9e33f25c630cef https://doi.org/10.1007/s00381-026-07438-y

View Full Paper

Ask AI

Bookmark

September 4, 2026Child s Nervous SystemOpen Access

Laser interstitial thermal therapy in pediatric neurosurgery: a prospective nationwide study on indications, safety, and early outcomes

View Full Paper

Ask AI

Bookmark

Authors

SNSilas Haahr Nielsen JFJon Foss-Skiftesvik TMTorstein Melling

Discussion

Member takes

Overview

Prospective cohort study demonstrates favorable safety and seizure control from laser interstitial thermal therapy in pediatric patients, suggesting it is a viable minimally invasive option.

Key Points

To evaluate the indications, safety profile, and early clinical outcomes of MRI-guided laser interstitial thermal therapy (LITT) in children, including the feasibility of concurrent stereotactic biopsy.
Prospective cohort study of consecutive pediatric patients (age ≤ 18 years, N=27) treated with LITT at the Danish national referral center from June 2021 to October 2025.
Indications included drug-resistant epilepsy (n=18) and intracranial tumors (n=9), with 10 patients undergoing same-session stereotactic biopsy.
Outcomes measured included intraoperative adverse events, new neurological deficits, hospital stay, 30-day readmissions, Engel class seizure status, and tumor response on follow-up MRI.
Zero intraoperative complications or 30-day readmissions occurred; transient neurological deficits developed in 8 patients and persistent deficits in 3, with hospital stay ≤ 2 days for 23 of 27 patients.
In epilepsy cases, seizure freedom (Engel class I) was achieved in 71% of patients at 6 months, 63% at 12 months, and 57% at 24 months.
Tumor control was documented on follow-up MRI in 4 of 5 cases over a median follow-up of 15 months, and same-session stereotactic biopsy was successfully performed in 10 patients without biopsy-related complications.

Cite This Study

Nielsen et al. (2026) studied this question.

synapsesocial.com/papers/6a9a85345d9e33f25c630cef https://doi.org/10.1007/s00381-026-07438-y

View Full Paper

Ask AI

Bookmark